Scholar Rock Holding Corp (OQ:SRRK)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 301 BINNEY STREET, 3RD FLOOR
CAMBRIDGE MA 02142
Tel: N/A
Website: https://scholarrock.com
IR: See website
<
Key People
Jay T. Backstrom
President, Chief Executive Officer, Director 		Edward H. Myles
Chief Financial Officer, Chief Operating Officer 		Caryn Parlavecchio
Chief Human Resource Officer
Junlin Ho
General Counsel, Corporate Secretary 		Jing L. Marantz
Chief Medical Officer 		 
Business Overview
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company's product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.
Financial Overview
For the nine months ended 30 September 2023, Scholar Rock Holding Corp revenues decreased from $33.2M to $0K. Net loss increased 26% to $119.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 20% to $78.6M (expense), Stock-based Compensation in SGA increase of 9% to $11.9M (expense).
Employees: 150 as of Mar 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $867.22M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$168.45M as of Dec 31, 2023
Net annual income (TTM): -$165.79M as of Dec 31, 2023
Free cash flow (TTM): -$145.30M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 77,866,281 as of Mar 14, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More